Utility of DNA microarrays for detection of viruses in acute respiratory tract infections in children. by Chiu, Charles Y et al.
UCSF
UC San Francisco Previously Published Works
Title
Utility of DNA microarrays for detection of viruses in acute respiratory tract infections in 
children.
Permalink
https://escholarship.org/uc/item/583588sx
Journal
The Journal of pediatrics, 153(1)
ISSN
0022-3476
Authors
Chiu, Charles Y
Urisman, Anatoly
Greenhow, Tara L
et al.
Publication Date
2008-07-01
DOI
10.1016/j.jpeds.2007.12.035
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Since January 2020 Elsevier has created a COVID-19 resource centre with free
information in English and Mandarin on the novel coronavirus COVID-19. The
COVID-19 resource centre is hosted on Elsevier Connect, the company's public
news and information website.
Elsevier hereby grants permission to make all its COVID-19-related research
that is available on the COVID-19 resource centre - including this research
content - immediately available in PubMed Central and other publicly funded
repositories, such as the WHO COVID database with rights for unrestricted
research re-use and analyses in any form or by any means with acknowledgement
of the original source. These permissions are granted for free by Elsevier
for as long as the COVID-19 resource centre remains active.
O
p
S
r
2
R
i
p
r
a
d
C
t
p
A
t
m
2
b
fl
l
r
g
t
p
a
b
p
(
A
C
D
E
F
H
H
7Utility of DNA Microarrays for Detection of Viruses in Acute
Respiratory Tract Infections in Children
CHARLES Y. CHIU, MD, PHD,* ANATOLY URISMAN, PHD,* TARA L. GREENHOW, MD, SILVI ROUSKIN, BS, SHIGEO YAGI, PHD,
DAVID SCHNURR, PHD, CAROLYN WRIGHT, MS, W. LAWRENCE DREW, MD, PHD, DAVID WANG, PHD, PEGGY S. WEINTRUB, MD,
JOSEPH L. DERISI, PHD, AND DON GANEM, MD, PHD
bjective To assess the utility of a panviral DNA microarray platform (Virochip) in the detection of viruses associated with
ediatric respiratory tract infections (RTIs).
tudy design The Virochip was compared with conventional direct fluorescent antibody (DFA)- and polymerase chain
eaction (PCR)-based testing for the detection of respiratory viruses in 278 consecutive nasopharyngeal aspirate samples from
22 children.
esults The Virochip was superior in performance to DFA, showing a 19% increase in the detection of 7 respiratory viruses
ncluded in standard DFA panels, and was similar to virus-specific PCR (sensitivity, 85% to 90%; specificity, >99%; positive
redictive value, 94% to 96%; negative predictive value, 97% to 98%) in the detection of
espiratory syncytial virus, influenza A, and rhinoviruses/enteroviruses. The Virochip
lso detected viruses not routinely tested for or missed by DFA and PCR, as well as
ouble infections and infections in critically ill patients that DFA failed to detect.
onclusions Given its favorable sensitivity and specificity profile and expanded spec-
rum for detection, microarray-based viral testing holds promise for clinical diagnosis of
ediatric RTIs. (J Pediatr 2008;153:76-83)
cute respiratory tract infections (RTIs) are the most common illnesses in humans
and are associated with significant morbidity and mortality. In children, viruses
are responsible for the majority of RTIs, with bacteria and other pathogens
hought to be responsible for fewer than 15% of cases.1 However, even with the best
ethods for viral detection currently available, a specific pathogen cannot be identified in
0% to 50% of RTIs.1-4
Existing viral diagnostic methods are limited in sensitivity and scope. Virus isolation
y culture takes days to weeks, and many viruses remain fastidious or unculturable. Direct
uorescent antibody (DFA) testing has a turnaround time of 2 hours, but may suffer from
ow sensitivity and is available for only a limited number of viruses.5 Polymerase chain
eaction (PCR) testing is rapid and highly sensitive, and has supplanted culture as the new
old standard for detecting respiratory viruses in research settings.3,4 However, most PCR
ests target only 1 virus at a time, making these assays cumbersome in routine clinical
ractice. For simultaneous detection of up to 20 viruses, a number of multiplex PCR
ssays have been proposed.3,4,6-10
Recently, DNA microarray testing has emerged as a promising new technology for
road-spectrum virus detection.11-13 We previously designed an in-house microarray
latform to detect all known viruses, as well as novel viruses related to known viral families
Virochip; University of California San Francisco [UCSF]).13,14 The Virochip consists of
dV Adenovirus
oV Coronavirus
FA Direct fluorescent antibody
V Enterovirus
luA/B Influenza A/B
MPV Human metapneumovirus
NPA Nasopharyngeal aspirate
PCR Polymerase chain reaction
RSV Respiratory syncytial virus
RT Reverse-transcriptase
RTI Respiratory tract infection
RV Rhinovirus
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U22 000 oligonucleotide probes representing all 1800 fully
r partially sequenced viruses in GenBank as of Fall 2004.
he performance of the Virochip in respiratory virus detec-
ion has been tested previously using virally infected tissue
ulture cells13 and in selected patient cohorts.15 To date, the
irochip has not been compared directly with standard diag-
ostic tests for viruses in a clinical setting; thus, in the present
tudy, we sought to compare the Virochip with conventional
linical DFA- and PCR-based testing in the detection of
espiratory viruses associated with RTIs in children.
METHODS
tudy Design
This study is a prospective case series of all consecutive
amples sent for viral DFA testing from pediatric patients
een at UCSF between December 2003 and June 2004. All
atient samples were collected according to protocols ap-
roved by UCSF’s Institutional Review Board.
ample Processing
Consecutive nasopharyngeal aspirate (NPA) samples sent
o the UCSF clinical laboratory for DFA were analyzed with the
ight Diagnostics Respiratory DFA Viral Screening and Iden-
ification Kit (Chemicon International, Temecula, CA). This kit
etects 7 common respiratory viruses: respiratory syncytial virus
RSV); influenza A and B (FluA and FluB); human parainflu-
nza virus types 1, 2, and 3 (HPIV-1, 2, and 3); and adenovirus
AdV). Remaining sample material was transferred into a sterile
4-mL conical tube, frozen, and stored at 80°C.
For blinded Virochip analysis, frozen NPA samples
ere thawed, and 200-L aliquots were used to extract RNA
sing the RNeasy Mini Kit (Qiagen Inc, Valencia, California)
ccording to the manufacturer’s protocol, including on-col-
mn DNase digestion. Microarrays used in this study were
dentical to those described previously (National Center for
iotechnology Information GEO platform GPL3429).16
NA samples were amplified and labeled using a round A/B
andom PCR method and hybridized to the Virochip as
eported previously.13 Microarrays were scanned with an
xon 4000B scanner and analyzed using Axon GenePix 6
oftware (Axon Instruments, Union City, California). All
icroarray data have been submitted to the National Center
or Biotechnology Information GEO database (accession
umber GSE10294).
irochip Data Analysis
Virochip data analysis was carried out in 2 stages. First,
ll microarrays were analyzed with the E-Predict algorithm,17
sing a significance value of P  .01 to identify microarrays
ith statistically significant viral hybridization patterns (176
f 278). To generate an optimized set of oligonucleotide
ntensity weights for the third-generation Virochip platform,
e took the remaining 102 presumably negative microarrays
nd manually fit a set of functions with the general equation h
tility of DNA Microarrays for Detection of Viruses in Acute Respirato 1  i ab a
p 1p if a i b;
w 1 if a i b; or w 0 if i b,
here w is a weight (value from 0 to 1) for a given oligonu-
leotide, i is the median of sum-normalized intensities of that
ligonucleotide across the 102 negative microarrays, and
ower boundary a is the median of medians of the sum-
ormalized intensities of all oligonucleotides. The upper
oundary condition b was expressed as b  a  c , where c
s a constant and  is the standard deviation of sum-normal-
zed intensities of the oligonucleotide across the 102 negative
icroarrays. A total of 40 weight sets with c and p as fitting
easurements were evaluated using E-Predict profile separa-
ion statistics on 6 rhinovirus (RV)-positive, 6 RSV-positive,
HPIV-3–positive, and 2 FluA-positive microarrays. The
ptimal performance was achieved with weights correspond-
ng to c  0.15 and p  1.5. These weights were used to
enerate negative null distributions based on the set of 102
egative microarrays mentioned above, and final microarray
irus determinations were made by E-Predict. A microarray
as considered E-predict–positive for a given virus if the
orresponding energy profile attained a significance value of
 .05.
CR Analysis
Blinded reverse-transcriptase (RT)-PCR assays for
SV, FluA, RV, and enterovirus (EV) were performed on
NA extracted from the frozen NPA samples at the Viral
nd Rickettsial Disease Laboratory, California Department
f Health Services. For detection of RSV, an RT-PCR
ssay for RSV targeting the fusion (F) gene was performed
sing the 1-step Access RT-PCR system as described
reviously.2 For detection of FluA, primers and fluorescent
robes targeting the highly conserved matrix (M) gene of
luA were used with the Roche LightCycler Real-Time
CR System (Roche Diagnostics, Indianapolis, Indiana) as
escribed previously.18 For detection of RV/EV, we first
an an in-house RT-PCR multiplex assay on randomly
rimed template cDNA using primers targeting the highly
onserved 5= untranslated region of RV15 and EV.19 Pos-
tive samples were identified by the presence of amplified
CR bands of the expected size on agarose gel electro-
horesis. Follow-up real-time PCR assays for RV/EV de-
ection on discrepant samples between the Virochip and
he in-house multiplex RT-PCR were then carried out
sing the Roche LightCycler Real-Time PCR System as
escribed previously.20
equence Confirmation of Virochip-Positive/
CR-Negative Samples
Confirmation of 2 Virochip-positive/PCR-negative
amples was done by PCR using alternative primers based on
igh-intensity microarray oligonucleotides and direct se-
ry Tract Infections in Children 77
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7uencing. The sequence from 1 case of RSV was 97% iden-
ical to a 155-bp fragment from the matrix (M) gene for RSV
ubgroup B strain 9320, and the sequence from 1 case of RV
as 96% identical to a 302-bp fragment from the VP4/VP2
egion for RV strain QPID03-0003. Another Virochip-pos-
tive/PCR-negative case (an EV) was confirmed by a repeat
un of the real-time PCR assay.20
linical Data Collection
After assay results for the NPA samples were obtained,
ubjects were identified, and a retrospective review of the
edical record was performed. Data were systematically col-
ected using a standard form that documented the following
nformation: age, sex, date and location of sample collection,
linical presentation, presence of immunocompromised state,
resence of acute respiratory failure, and DFA result. Lo-
ation of sample collection was classified as outpatient
clinic or emergency department) or hospital admission.
resenting illness was defined as an upper RTI (ie, cough
nd/or congestion with or without fever or a clinician’s
iagnosis), lower RTI (ie, clinician’s diagnosis of asthma
xacerbation, bronchiolitis, croup, or pneumonia), or no
espiratory illness (eg, febrile illness, seizures, or DFA
ollected on a routine basis, such as before transplantation
urgery). Immunocompromised patients were defined as
hildren with solid organ or bone marrow transplants,
ongenital or acquired immune deficiencies (including
hose on chemotherapy), or human immunodeficiency vi-
us. Patients with respiratory failure were defined as chil-
able 1. Demographic and clinical data according to
Variable
Number (%)
of subjects
Age
( standard deviation),
years M
ll subjects 222 (100%) 3.5 (4.4) 1
espiratory illness 157 (71%) 3.2 (4.2)
pper RTI 59 (27%) 3.5 (4.3)
ronchiolitis/croup 42 (19%) 1.2 (1.5)
neumonia 51 (23%) 4.0 (4.9)
sthma exacerbation 13 (6%) 3.9 (2.7)
o respiratory
illness
65 (29%) 4.0 (4.9)
SV 42 (19%) 1.5 (1.2)
luA/FluB 25 (11%) 3.8 (4.1)
PIV 10 (5%) 2.8 (4.5)
icomavirus 35 (16%) 3.6 (4.6)
MPV 4 (2%) 3.1 (2.8)
oV 3 (1%) 4.2 (2.6)
dV 3 (1%) 3.8 (1.8)
o pathogen or
other
106 (48%) 4.0 (5.0)
emographic and clinical data were collected for all 222 enrolled subjects in the study
atients with more than 1 sample collected, only the first-time sample was used in this
umber of samples reported in Figure 1 (n 278), because multiple samples were collect
ecause some of the cases are double-virus infections.ren who developed acute respiratory decompensation ne- o
8 Chiu et alessitating mechanical ventilation as a result of their
espiratory illness. For patients with more than 1 sample, a
rst-time sample was defined as the earliest sample col-
ected during a single hospitalization or illness.
RESULTS
emographic and Clinical Data
We analyzed a total of 278 NPA samples collected from
22 children for the presence of viruses using DFA and
irochip. Demographic and clinical data for the 222 patients
re given in Table I. Most patients (73%) were hospitalized.
pproximately 71% of the enrolled patients (n 157) had an
cute RTI, and the remaining patients (n  65) had DFA
ent for other reasons, most often a nonrespiratory febrile
llness (n  46). Eighteen percent of the patients (n  39)
ere immunocompromised, and 8% (n  17) developed
espiratory failure necessitating mechanical ventilation as a
esult of their illness. Most of the subjects with RSV were
ounger (mean age, 1.5 years) and required hospitalization
76%), whereas subjects with influenza tended to be older (mean
ge, 4.1 years) and were treated mainly as outpatients (64%). All
ases of human metapneumovirus (HMPV), coronavirus (CoV),
nd AdV were in hospitalized patients. The majority of viral
nfections in immunocompromised subjects (60%) were due to
icornaviruses.
etection of Viruses by DFA and the Virochip
Figure 1 shows the spectrum and frequency of detection
ss and viral pathogen
sex Hospitalization
Respiratory
failure
Immunocompromised
status
1%) 163 (73%) 17 (8%) 39 (18%)
9%) 105 (67%) 11 (7%) 17 (11%)
6%) 25 (42%) 1 (2%) 10 (17%)
0%) 29 (69%) 1 (2%) 0 (0%)
3%) 45 (88%) 9 (18%) 7 (14%)
2%) 12 (92%) 0 (0%) 0 (0%)
8%) 58 (89%) 6 (9%) 22 (34%)
5%) 32 (76%) 3 (7%) 1 (2%)
2%) 9 (36%) 2 (8%) 2 (8%)
0%) 7 (70%) 1 (10%) 2 (20%)
4%) 27 (77%) 4 (11%) 9 (26%)
0%) 4 (100%) 1 (25%) 0 (0%)
3%) 3 (100%) 1 (33%) 1 (33%)
00%) 3 (100%) 1 (33%) 0 (0%)
5%) 83 (78%) 6 (6%) 24 (23%)
ratified according to type of presenting illness and virus detected by the Virochip. For
s. The total number of cases summarized in this table (n  222) differs from the total
ome patients. The sum of the percentages of viruses detected by the Virochip is100%,illne
ale
36 (6
92 (5
39 (6
21 (5
27 (5
12 (9
44 (6
23 (5
18 (7
5 (5
19 (5
2 (5
1 (3
3 (1
69 (6
and st
analysi
ed for sf different viruses by the 2 methods. In patients with RTI,
The Journal of Pediatrics • July 2008
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Uigure 1. Viruses detected by DFA and Virochip. A total of 278 nasopharyngeal aspirate samples from 222 patients were analyzed by DFA and Virochip.
umber of NPA samples positive for a virus in the DFA panel (“DFA virus,” light blue), positive for a virus not found in the DFA panel (“non-DFA
irus,” pink), and negative (negative, yellow) by DFA (A) and by Virochip (B), plotted as a proportion of all samples stratified by presenting illness (rows).
, Number of NPA samples positive for RSV, FluA/B, HPIV, RV, EV, CoV, AdV, and HMPV plotted as a proportion of all samples stratified by
resenting illness (rows). The term “double” denotes instances of infections with 2 viruses (see Table II; available at www.jpeds.com), and “other”
orresponds to viruses that are not typically considered respiratory pathogens (see text). The respiratory illnesses corresponding to 12 samples from 8
atients (3.6%) are assigned to 2 categories.
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8FA detected a virus in only 36% of the samples, whereas the
irochip detected a virus in 64%, for a 75% improvement in
he rate of detection. Detection of viruses not included in the
FA panel (non-DFA viruses) accounted for approximately
/3 of all Virochip-positive identifications. Among these non-
FA viruses, picornaviruses was the largest group (74% of
amples positive for a non-DFA virus, or 16% of all samples
rom patients with RTIs). These picornaviruses included 16
Vs, 14 EVs, and 1 parechovirus. Besides the picornaviruses,
he Virochip identified 4 HMPV and 2 CoV infections from
atients with RTIs. Human cytomegalovirus–like sequences
ere detected in 1 sample from 1 febrile patient with pneu-
onia. In 7 samples, the Virochip detected viruses not typi-
ally associated with respiratory disease and of doubtful clin-
cal significance; these viruses included polyomaviruses (SV40
nd JC viruses), plant viruses commonly found in the gastro-
ntestinal tract (nanoviruses and geminiviruses),21 and bovine
eukemia virus, a virus ubiquitous in cow’s milk.22 A virus was
etected in a higher proportion of patients with upper RTIs
68%) and bronchiolitis (77%) than in those with pneumonia
54%) or asthma exacerbation (41%). In patients with non-
espiratory illnesses (typically febrile illnesses of uncertain
rigin), the Virochip detected a virus in 30% of the samples,
ith the majority accounted for by picornaviruses, whereas
FA detected a virus in only 3%. Overall, at least 1 of the
DFA viruses was identified by Virochip in 31% of the
TI samples (n  86), compared with 25% identified by
FA (n  72), corresponding to a 19% overall increase in
etection by the Virochip compared with DFA (P  .01 by
2 analysis).
irochip Detection of Double and Critical
iral Infections
The Virochip detected 13 cases of simultaneous infec-
ion by 2 viruses (9% of Virochip-positive samples, 5% of all
amples; Table II; available at www.jpeds.com). In contrast,
FA detected no cases of double infection. The Virochip also
etected a viral pathogen in 12 of 17 critically ill patients who
eveloped respiratory failure necessitating mechanical venti-
ation, whereas a virus was detected by DFA in only 5 such
atients. Two double infections (1 case of FluA/AdV and 1
ase of RSV/RV) were identified among these life-threaten-
ng cases.
omparison of the Virochip with PCR
To assess Virochip results that were discordant with
FA and overall sensitivity and specificity, we carried out
T-PCR assays for RSV, FluA, and RV/EV, the 3 major
roups of viruses detected by the Virochip (Figure 2). For
etection of RSV and FluA, the overall sensitivity of the
irochip (86%) relative to PCR was significantly better than
hat of DFA (71%; P  .05 by 2 analysis). The correspond-
ng specificities were 	 99%. There was also a greater overlap
n positives between Virochip and PCR than between DFA
nd PCR for these 2 viruses; 16 of of 18 (89%) of Virochip- i
0 Chiu et alositive/DFA-negative RSV and FluA samples were con-
rmed to be true positives by PCR (Figure 2; Venn diagram).
For detection of RV/EV, we first used an in-house
T-PCR multiplex assay based on methods reported previ-
usly.15,19 Using this assay, 31 NPA samples were positive by
oth Virochip and PCR, 18 NPA samples were Virochip-
ositive/PCR-negative, and 5 NPA samples were Virochip-
egative/PCR-positive. Because these results were inconsis-
ent with the rates of detection using clinically validated PCR
ssays for the other viruses (RSV and FluA), we further
nalyzed the 23 discrepant samples in a blinded fashion using
more sensitive clinically validated real-time PCR assay for
V/EV.20 Results obtained by combining these 2 assays show
hat the Virochip had overall high sensitivity (90%) and
pecificity (99%) for detection of RV/EV (Figure 2C).
irochip Detection of PCR-Negative Cases of
espiratory Virus Infection
Six cases (3 picornavirus, 2 RSV, and 1 FluA) detected
y the Virochip tested negative in the corresponding PCR
ssays (Figure 2). We hypothesized that most of these cases
ere viral strains that had failed detection with standard PCR
rimers. To investigate this possibility, we recovered viral
equences from 2 Virochip-positive/PCR-negative cases (1
V and 1 RSV) and separately confirmed a case of EV that
as Virochip-positive and previously PCR-negative by re-
eating the real-time PCR assay. Similar attempts to confirm
he remaining 3 Virochip-positive/PCR-negative cases with
he limited amount of sample available were unsuccessful.
hus, at least 3 of the 6 Virochip-positive/PCR-negative
epresent PCR false-negatives, and, consequently, the re-
orted sensitivity of the Virochip may be underestimated.
DISCUSSION
This study of pediatric RTIs used a DNA microarray
hat aims to detect all known viral species simultaneously.
he most common viral pathogens identified were RSV
19%), picornaviruses (16%), and FluA/B (11%). Notably,
ost viruses detected in the respiratory tracts of the patients
ith nonrespiratory illnesses and in the immunocompromised
atients were picornaviruses. These findings are consistent
ith the observation that asymptomatic RV infections can be
een in 4% to 12% of healthy individuals and suggest that
mmunocompromised hosts may be more susceptible to col-
nization or overt respiratory illness by picornaviruses.23 Our
requency of detection of 16% for picornaviruses is consistent
ith that of a previously published report (18% RVs, 2.9%
Vs) that also used consecutive NPA samples.24
Our comparison of the Virochip with DFA demon-
trates that the former has superior sensitivity for respiratory
irus detection. Importantly, about 50% of the overall increase
n detection rate corresponds to samples with inconclusive
FA results due to low cellular content. Unlike DFA, nucleic
cid detection methods, such as microarray and PCR, are
apable of detecting free viral particles in addition to virus-
nfected cells. Another significant advantage of a panviral
The Journal of Pediatrics • July 2008
F
c
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Uigure 2. Comparison of the performance of DFA and Virochip relative to PCR. DFA and Virochip were compared with specific PCR using 2  2
ontingency tables and Venn diagram analysis for detection of RSV (A) and FluA (B). In addition, Virochip was compared with specific PCR using a 2  2
ontingency table for detection of RV and EV, 2 picornaviruses not tested for by DFA (C). Because the specific PCR assays for RV/EV used here do not
dequately distinguish RV from EV, results are reported as the total number of RV/EV-positive cases.
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8icroarray over DFA is the ability to screen for all known
iruses simultaneously. DFA panels in current clinical use do
ot test for RV/EV, HMPV, or CoV, which in our study
omposed more than 1/3 of the detected viruses in the pa-
ients with RTIs.
The 17 patients presenting with illness severe enough to
equire mechanical ventilation included 3 cases of critical RV
nfection, including 1 immunocompromised individual. RV
nfection is thought to comprise a spectrum of disease ranging
rom asymptomatic infection to life-threatening childhood
neumonia.25 Our findings of cases of critical respiratory tract
llness associated with RV infection is consistent with grow-
ng evidence linking RV with hospitalizations in young chil-
ren.26 The Virochip was also superior to DFA for detecting
ouble-virus infections. Two cases of double infection, in
hich both viruses could be detected by DFA in principle,
ere characterized as single-virus infections by DFA. Previ-
us studies have suggested that double-virus infections are
ssociated with greater severity of RTI.27 Higher efficiency of
he microarray in detecting critical as well as double-virus
nfections is an important advantage of the method; timely
etection of such infections may allow clinicians to avoid
nnecessary antibiotics and invasive procedures and begin
ppropriate antiviral treatment, if available.
Besides being a highly parallel methodology that uses
housands of oligonucleotide probes for simultaneous detec-
ion, DNA microarray platforms like the Virochip are ex-
andable and adaptable. The automated oligonucleotide de-
ign allows straightforward addition of new probes for better
etection of known viruses, as well as expanded coverage of
ovel or evolving viral species.16,28,29 DNA microarrays also
an be used for detection of nonviral pathogens, including
acteria and fungi.30 Interestingly, in this study, the Virochip
etected Streptococcus pyogenes bacteriophages in a sample
rom a patient with aspiration pneumonia who also had a
ositive sputum culture for Streptococcus pyogenes. This result
uggests a possible strategy of using phage sequences as an
ndirect means of detecting bacterial pathogens.
Despite its panviral scope, the Virochip detected a virus
n only 64% of RTI cases overall. Although comparable with
ndings from other detection methods,1-4,8,9 this result is
ikely an underestimation of the true number of positives
rising from several factors. First, some samples may have
een missed by the Virochip due to low virus titers at the
etection limits of PCR. Second, the use of RNA (rather than
NA) as the source material in this study may have given rise
o lower-than-expected rates of detection of DNA viruses
uch as AdVs, herpesviruses, and parvoviruses. The Virochip
ay not have detected any cases of human bocavirus, a
ecently described parvovirus,31 because this virus shares low
equence identity to parvovirus sequences currently repre-
ented on the Virochip. Finally, 32% of patients with RTIs in
his study were diagnosed with pneumonia, 35% of which
ere hospital-associated. Many of these cases of pneumonia
ay be nonviral in origin, as suggested by previous epidemi-
logic studies of pneumonia in hospitalized children.32,33
2
e
2 Chiu et alUsing custom PCR primers, we confirmed at least 3 of
he 6 microarray-positive/PCR-negative cases (1 RSV, 1 RV,
nd 1 EV) as true positive tests for viruses. Detection of such
ases by microarray is not unexpected, because the Virochip
ses multiple probes that are derived from different sites in
he viral genome and have a higher tolerance for sequence
ismatches than the primers used in specific PCR. This
esults in improved detection of divergent viruses.14,34 We
uspect that the microarray-positive/PCR-negative cases of
irus infection were missed by clinical PCR likely due to
ismatches between primer and target sequences,35 although
imited specimen availability affected our ability to show this
efinitively.
Although the prospect of comprehensive viral detection
ith a single microarray assay is appealing, several challenges
ust be addressed before the use of this technology can
ecome practical in clinical diagnosis. First, setting up the
echnology entails significant initial startup costs, including
he cost of the microarray printer and viral oligonucleotides,
s well as ongoing material and labor costs. Second, the
urnaround time for the assay is currently 24 hours; it may
e possible to decrease the processing duration by using
ltra-rapid polymerases for amplification or controlled agita-
ion techniques during hybridization. Third, reproducibility
nd consistent array quality are of concern. In our study, none
f the microarray assays had to be repeated, and the inherent
robe redundancy built into the method makes the assay
obust for the purpose of virus detection. For example, of the
00 oligonucleotide probes on the Virochip designed to hy-
ridize to rhinoviruses, as few as 4 high-intensity oligonucle-
tides are sufficient to make a successful virus identification.
tatistical methods for interpreting the microarray data, as
xemplified by E-Predict, can be completely automated, al-
owing ease of use and freedom from operator bias. Smaller
icroarrays aimed at detecting targeted virus sets (eg, respi-
atory viruses only) would reduce costs and simplify issues of
eproducibility, quality control, and data analysis.
Looking to the future, we can envision 2 possible ap-
roaches to using viral detection microarrays in clinical prac-
ice. One approach would be to use the platform for direct
iagnosis of respiratory infections, as reported here. An alter-
ative approach could be to deploy a viral microarray as an
nstrument of discovery rather than of routine detection, with
he goal of identifying divergent or unexpected viruses that
lude diagnosis using conventional methods. Once a new
andidate pathogen was identified, a specific PCR-based or
FA-based assay could then be developed to detect the virus
ith a high degree of sensitivity in clinical samples. In this
cenario, the microarray assay would complement rather than
eplace existing diagnostic techniques such as PCR.
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8able II. Detection of double and critical infections b
DFA* Virochip (virus 1) Viroch
ouble infections
RSV FluA RSV
FluA FluA AdV
RSV EV RSV
RSV Parechovirus RSV
RSV EV RSV
RSV RV RSV
FluA FluA Nanoviru
Negative HMPV Polyoma
Negative FluA Polyoma
Negative Parvovirus (AAV-5) RV
Negative HPIV-1 Bovine le
Negative Picomavirus (Aichi) Polyoma
ritical infections
FluA FluA, AdV
FluA FluA
RSV RSV, RV
RSV RSV
HPIV-1 HPIV-1
Negative RSV
Negative RV
Negative HMPV, polyomavirus
Negative CoV
Negative RV
Negative EV
Negative Streptococcus pyogenes
bacteriophage
Negative (5) Negative (5)
PIV-1, human parainfluenza virus type 1; AAV-5, adeno-associated virus type 5.
FA and Virochip results corresponding to cases of double infection (n  12) and criti
correspond to the top and second statistically significant Virochip predictions, respec
No cases of double infection were detected by DFA.y Virochip and DFA†
ip (virus 2) Presenting illness
Bronchiolitis
Pneumonia
Bronchiolitis
Bronchiolitis
Bronchiolitis
Bronchiolitis
s Upper RTI
virus (JC virus) Pneumonia
virus (SV40) Pneumonia
Upper RTI
ukemia virus Fever
virus (JC virus) Fever
Community-acquired pneumonia
Community-acquired pneumonia
Bronchiolitis
Community-acquired pneumonia
Community-acquired pneumonia
Upper RTI progressing to respiratory failure
Pneumonia in immunocompromised patient
Apnea with pneumonia
Fever with seizures
Fever and respiratory distress
Aspiration pneumonitis
Aspiration pneumonia
Aspiration pneumonia (2), apnea (1), pulmonary
hypertension (1), gastroenteritis (1)
cal respiratory illness requiring mechanical ventilation (n  17) are shown. Virus 1 and Virus
tively.Viruses that may be commensal or food-associated.
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